JP2012528599A - リプログラミングｔ細胞および造血細胞 - Google Patents

リプログラミングｔ細胞および造血細胞 Download PDF

Info

Publication number
JP2012528599A
JP2012528599A JP2012514169A JP2012514169A JP2012528599A JP 2012528599 A JP2012528599 A JP 2012528599A JP 2012514169 A JP2012514169 A JP 2012514169A JP 2012514169 A JP2012514169 A JP 2012514169A JP 2012528599 A JP2012528599 A JP 2012528599A
Authority
JP
Japan
Prior art keywords
cells
cell
reprogramming
ips
cell population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012514169A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012528599A5 (cg-RX-API-DMAC10.html
Inventor
マシュー ブラウン，
エリザベス ロンドン ドミンゲス，
ランディー リーリッシュ，
エミール ニューエイサー，
ディーピカ ラジェシュ，
アマンダ マック，
Original Assignee
セルラー ダイナミクス インターナショナル， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42357428&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2012528599(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by セルラー ダイナミクス インターナショナル， インコーポレイテッド filed Critical セルラー ダイナミクス インターナショナル， インコーポレイテッド
Publication of JP2012528599A publication Critical patent/JP2012528599A/ja
Publication of JP2012528599A5 publication Critical patent/JP2012528599A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/605—Nanog
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/608—Lin28
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
    • Y02E60/10—Energy storage using batteries

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2012514169A 2009-06-05 2010-06-04 リプログラミングｔ細胞および造血細胞 Pending JP2012528599A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18454609P 2009-06-05 2009-06-05
US61/184,546 2009-06-05
US24011609P 2009-09-04 2009-09-04
US61/240,116 2009-09-04
PCT/US2010/037376 WO2010141801A2 (en) 2009-06-05 2010-06-04 Reprogramming t cells and hematophietic cells

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2014171199A Division JP2014217393A (ja) 2009-06-05 2014-08-26 リプログラミングｔ細胞および造血細胞
JP2017052542A Division JP2017104140A (ja) 2009-06-05 2017-03-17 リプログラミングｔ細胞および造血細胞

Publications (2)

Publication Number Publication Date
JP2012528599A true JP2012528599A (ja) 2012-11-15
JP2012528599A5 JP2012528599A5 (cg-RX-API-DMAC10.html) 2013-02-14

Family

ID=42357428

Family Applications (9)

Application Number Title Priority Date Filing Date
JP2012514169A Pending JP2012528599A (ja) 2009-06-05 2010-06-04 リプログラミングｔ細胞および造血細胞
JP2014171199A Pending JP2014217393A (ja) 2009-06-05 2014-08-26 リプログラミングｔ細胞および造血細胞
JP2017052542A Pending JP2017104140A (ja) 2009-06-05 2017-03-17 リプログラミングｔ細胞および造血細胞
JP2017229990A Pending JP2018029622A (ja) 2009-06-05 2017-11-30 リプログラミングｔ細胞および造血細胞
JP2018138431A Active JP6865199B2 (ja) 2009-06-05 2018-07-24 リプログラミングｔ細胞および造血細胞
JP2018138432A Pending JP2018198604A (ja) 2009-06-05 2018-07-24 リプログラミングｔ細胞および造血細胞
JP2019172230A Pending JP2020022462A (ja) 2009-06-05 2019-09-20 リプログラミングｔ細胞および造血細胞
JP2020070196A Pending JP2020124197A (ja) 2009-06-05 2020-04-09 リプログラミングｔ細胞および造血細胞
JP2020160507A Pending JP2021000131A (ja) 2009-06-05 2020-09-25 リプログラミングｔ細胞および造血細胞

Family Applications After (8)

Application Number Title Priority Date Filing Date
JP2014171199A Pending JP2014217393A (ja) 2009-06-05 2014-08-26 リプログラミングｔ細胞および造血細胞
JP2017052542A Pending JP2017104140A (ja) 2009-06-05 2017-03-17 リプログラミングｔ細胞および造血細胞
JP2017229990A Pending JP2018029622A (ja) 2009-06-05 2017-11-30 リプログラミングｔ細胞および造血細胞
JP2018138431A Active JP6865199B2 (ja) 2009-06-05 2018-07-24 リプログラミングｔ細胞および造血細胞
JP2018138432A Pending JP2018198604A (ja) 2009-06-05 2018-07-24 リプログラミングｔ細胞および造血細胞
JP2019172230A Pending JP2020022462A (ja) 2009-06-05 2019-09-20 リプログラミングｔ細胞および造血細胞
JP2020070196A Pending JP2020124197A (ja) 2009-06-05 2020-04-09 リプログラミングｔ細胞および造血細胞
JP2020160507A Pending JP2021000131A (ja) 2009-06-05 2020-09-25 リプログラミングｔ細胞および造血細胞

Country Status (10)

Country Link
US (4) US8741648B2 (cg-RX-API-DMAC10.html)
EP (3) EP2548950B1 (cg-RX-API-DMAC10.html)
JP (9) JP2012528599A (cg-RX-API-DMAC10.html)
KR (3) KR101772860B1 (cg-RX-API-DMAC10.html)
CN (3) CN105925535A (cg-RX-API-DMAC10.html)
AU (1) AU2010254811B2 (cg-RX-API-DMAC10.html)
CA (2) CA2952805C (cg-RX-API-DMAC10.html)
DK (3) DK3150701T3 (cg-RX-API-DMAC10.html)
IL (2) IL216707B (cg-RX-API-DMAC10.html)
WO (1) WO2010141801A2 (cg-RX-API-DMAC10.html)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013528397A (ja) * 2010-06-15 2013-07-11 セルラー ダイナミクス インターナショナル， インコーポレイテッド 少量の末梢血からの人工多能性幹細胞の作製
JP2015146803A (ja) * 2014-01-10 2015-08-20 学校法人 聖マリアンナ医科大学 メラノサイトの分化誘導方法
US9206394B2 (en) 2010-02-03 2015-12-08 The University Of Tokyo Method for reconstructing immune function using pluripotent stem cells
WO2018143243A1 (ja) * 2017-02-03 2018-08-09 国立大学法人神戸大学 人工多能性幹細胞の作製方法
JP2018526992A (ja) * 2015-08-31 2018-09-20 アイ ピース，インコーポレイテッド 多能性幹細胞製造システム、幹細胞の誘導方法、幹細胞の浮遊培養方法、幹細胞の浮遊培養器、人工多能性幹細胞の作製方法、及び動物細胞から特定の体細胞を作製する方法
JPWO2020013315A1 (ja) * 2018-07-13 2021-08-02 国立大学法人京都大学 γδＴ細胞の製造方法
JP2022513045A (ja) * 2018-11-16 2022-02-07 セルジーン コーポレイション 改善されたｔ細胞製造プロセス

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105925535A (zh) 2009-06-05 2016-09-07 细胞动力国际有限公司 重编程t细胞和造血细胞的方法
JPWO2011096482A1 (ja) 2010-02-03 2013-06-13 国立大学法人 東京大学 多能性幹細胞を用いた免疫機能再建法
CN103097521A (zh) * 2010-04-16 2013-05-08 学校法人庆应义塾 人工多能性干细胞的制造方法
EP2601289B1 (en) * 2010-08-04 2017-07-12 Cellular Dynamics International, Inc. Reprogramming immortalized b cells
WO2012109208A2 (en) 2011-02-08 2012-08-16 Cellular Dynamics International, Inc. Hematopoietic precursor cell production by programming
CA2875858C (en) 2011-06-21 2022-05-03 Georgia Tech Research Corporation Adhesive signature-based methods for the isolation of stem cells and cells derived therefrom
WO2013070468A1 (en) * 2011-11-08 2013-05-16 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
US10428309B2 (en) 2011-12-01 2019-10-01 New York Stem Cell Foundation, Inc. Systems and methods for producing stem cells and differentiated cells
WO2013082509A1 (en) 2011-12-01 2013-06-06 The New York Stem Cell Foundation Automated system for producing induced pluripotent stem cells or differentiated cells
EP2853590B1 (en) * 2012-05-22 2018-11-07 The University of Tokyo Method for producing antigen-specific t cells
WO2014165663A1 (en) 2013-04-03 2014-10-09 Cellular Dynamics International, Inc. Methods and compositions for culturing endoderm progenitor cells in suspension
EP3789487A1 (en) 2013-04-03 2021-03-10 Memorial Sloan Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
US10738323B2 (en) 2013-07-12 2020-08-11 Cedars-Sinai Medical Center Generation of induced pluripotent stem cells from normal human mammary epithelial cells
CN103695469B (zh) * 2013-11-12 2017-01-11 中山大学 一种制备cd44基因缺陷小鼠诱导多能干细胞的方法
CN120536341A (zh) * 2014-03-04 2025-08-26 菲特治疗公司 改良的重编程方法和细胞培养平台
US10023879B2 (en) 2014-06-04 2018-07-17 Fate Therapeutics, Inc. Minimal volume reprogramming of mononuclear cells
AU2015290554A1 (en) * 2014-07-18 2017-03-09 Kyoto University Method for inducing T cells for cell-based immunotherapy from pluripotent stem cells
US10444227B2 (en) 2014-08-19 2019-10-15 FUJIFILM Cellular Dynamics, Inc. Neural networks formed from cells derived from pluripotent stem cells
JP6581655B2 (ja) 2014-10-14 2019-09-25 フジフィルム セルラー ダイナミクス，インコーポレイテッド 多能性幹細胞由来ケラチノサイトの生成およびケラチノサイト培養の維持
RU2756247C2 (ru) * 2014-11-17 2021-09-28 Эдисет Био, Инк. Генетически модифицированные гамма дельта т-клетки
EP3294342A4 (en) 2015-05-08 2018-11-07 President and Fellows of Harvard College Universal donor stem cells and related methods
US11162070B2 (en) 2015-09-08 2021-11-02 FUJIFILM Cellular Dynamics, Inc. MACS-based purification of stem cell-derived retinal pigment epithelium
CN114807035B (zh) 2015-09-08 2024-02-02 (由卫生与公众服务部部长代表的)美利坚合众国 临床级别视网膜色素上皮细胞的可再现的分化方法
WO2017044853A1 (en) * 2015-09-09 2017-03-16 Trustees Of Tufts College Methods of generating neural stem cells
EP3365429B1 (en) 2015-10-19 2020-03-11 FUJIFILM Cellular Dynamics, Inc. Production of virus-receptive pluripotent stem cell (psc)-derived hepatocytes
WO2017070333A1 (en) 2015-10-20 2017-04-27 Cellular Dynamics International, Inc. Multi-lineage hematopoietic precursor cell production by genetic programming
CN106609283A (zh) * 2015-10-26 2017-05-03 潘雨堃 一种利用转座子进行多基因同时操作的方法
JP6976960B2 (ja) * 2015-11-27 2021-12-08 カーサリクス プロプライエタリー リミテッド 遺伝子改変された細胞およびその使用
US9913865B2 (en) * 2015-12-28 2018-03-13 Ingeneron Inc. Induced pacemaker and Purkinje cells from adult stem cells
EP3397753B1 (en) 2015-12-30 2021-10-27 FUJIFILM Cellular Dynamics, Inc. Microtissue formation using stem cell-derived human hepatocytes
CA3010764A1 (en) * 2016-01-12 2017-07-20 Lonza Walkersville, Inc. Methods and vectors to produce vector free induced pluripotent stem cells
CN107022522A (zh) * 2016-02-01 2017-08-08 溯源生命科技股份有限公司 脐带血cd34阳性细胞向间充质干细胞的直接转分化技术
ES2904882T3 (es) * 2016-04-29 2022-04-06 Virogin Biotech Canada Ltd Vectores de HSV con replicación mejorada en células cancerosas
US11572545B2 (en) 2016-06-16 2023-02-07 Cedars-Sinai Medical Center Efficient method for reprogramming blood to induced pluripotent stem cells
US10221395B2 (en) 2016-06-16 2019-03-05 Cedars-Sinai Medical Center Efficient method for reprogramming blood to induced pluripotent stem cells
AU2017290805B2 (en) 2016-07-01 2023-11-16 Research Development Foundation Elimination of proliferating cells from stem cell-derived grafts
AU2017313065B2 (en) 2016-08-16 2021-06-24 Fujifilm Cellular Dynamics Inc. Methods for differentiating pluripotent cells
JP7215994B2 (ja) 2016-09-06 2023-01-31 ザ チルドレンズ メディカル センター コーポレーション 人工多能性幹細胞由来の免疫細胞
JP7212615B2 (ja) 2016-10-05 2023-01-25 フジフィルム セルラー ダイナミクス，インコーポレイテッド 多能性幹細胞からｈｌａホモ接合免疫細胞への指向分化方法
CA3038690A1 (en) 2016-10-05 2018-04-12 FUJIFILM Cellular Dynamics, Inc. Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
US11458225B2 (en) 2016-11-09 2022-10-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 3D vascularized human ocular tissue for cell therapy and drug discovery
US12215349B2 (en) * 2016-12-13 2025-02-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preparing an isolated or purified population of thymic emigrant cells and methods of treatment using same
KR20240095477A (ko) * 2017-01-13 2024-06-25 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 면역조작된 만능 세포
WO2018147801A1 (en) 2017-02-07 2018-08-16 Agency For Science, Technology And Research Methods and kits for generating mimetic innate immune cells from pluripotent stem cells
EP3606341A4 (en) * 2017-04-04 2021-04-21 The Board of Trustees of the Leland Stanford Junior University PREPARATION, EXPANSION AND USES OF ADULT PLURIPOTENT STEM CELLS
CN110891967B (zh) * 2017-04-18 2025-03-14 富士胶片细胞动力公司 抗原特异性免疫效应细胞
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
EP3638775A1 (en) * 2017-06-13 2020-04-22 Fate Therapeutics, Inc. Compositions and methods for inducing myeloid suppressive cells and use thereof
US11572544B2 (en) 2017-06-14 2023-02-07 The Children's Medical Center Corporation Hematopoietic stem and progenitor cells derived from hemogenic endothelial cells by episomal plasmid gene transfer
US10378070B2 (en) * 2017-09-07 2019-08-13 Kyoto University Vector and gene introduction agent for monitoring and visualizing cell differentiation using expression of micro RNA as indicator and monitoring and visualizing method using thereof
US20200345789A1 (en) * 2017-10-06 2020-11-05 Thyas, Co. Ltd. Production method for ips cell-derived population of genetically diverse t cells
GB201805683D0 (en) * 2018-04-05 2018-05-23 Touchlight Ip Ltd Reprogramming vectors
WO2019204817A1 (en) 2018-04-20 2019-10-24 FUJIFILM Cellular Dynamics, Inc. Method for differentiation of ocular cells and use thereof
CN108642083B (zh) * 2018-04-28 2022-03-22 安徽中盛溯源生物科技有限公司 一种将t细胞高效诱导成多能干细胞的重编程方法
CA3106403A1 (en) 2018-07-15 2020-01-23 Enochian BioPharma, Inc. Methods and compositions using recombinant dendritic cells for cancer therapy
CN112996524B (zh) 2018-11-07 2024-10-22 爱平世股份有限公司 医药品组合物以及化妆品组合物
CA3119041A1 (en) 2018-11-19 2020-05-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Biodegradable tissue replacement implant and its use
EP3884042A4 (en) * 2018-11-21 2022-08-24 Agency For Science, Technology And Research GENERATION OF TIRES AND COPPER CELLS
AU2019386140B2 (en) 2018-11-28 2026-05-28 Board Of Regents, The University Of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
EP3886874B1 (en) 2018-11-29 2024-12-11 Board of Regents, The University of Texas System Methods for ex vivo expansion of natural killer cells and use thereof
WO2020197319A1 (ko) * 2019-03-28 2020-10-01 한국생명공학연구원 면역세포의 제조방법 및 그의 용도
US20220213434A1 (en) 2019-05-10 2022-07-07 The Regents Of The University Of California Modified pluripotent cells
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
JP7343881B2 (ja) * 2019-06-10 2023-09-13 アイ ピース，インコーポレイテッド 赤血球除去装置、単核球回収器、細胞培養装置、細胞培養システム、細胞培養方法、及び単核球の回収方法
WO2021013669A1 (en) * 2019-07-24 2021-01-28 Miltenyi Biotec B.V. & Co. KG Assay for identifing colony-forming cells
KR20220130158A (ko) 2020-01-23 2022-09-26 더 칠드런스 메디칼 센터 코포레이션 인간 만능 줄기 세포로부터의 무-간질 t 세포 분화
US11091524B1 (en) 2020-04-22 2021-08-17 Houston Gene Therapeutics Llc Compositions for treatment of vascular disease
JP2023531378A (ja) 2020-05-28 2023-07-24 エーゼットセラピーズ， インコーポレイテッド 神経変性疾患を治療するためのＣＡＲ－Ｔｒｅｇ系療法
KR20230019453A (ko) 2020-05-29 2023-02-08 후지필름 셀룰러 다이내믹스, 인코포레이티드 망막 색소 상피 세포 및 광수용체의 이중 세포 응집체 및 이의 사용 방법
IL298254A (en) 2020-05-29 2023-01-01 Fujifilm Cellular Dynamics Inc Double layer of retinal pigment epithelium and photoreceptors and their uses
EP4635972A3 (en) 2020-07-20 2025-12-24 Enanta Pharmaceuticals, Inc. Functionalized peptides as antiviral agents
JPWO2022059780A1 (cg-RX-API-DMAC10.html) * 2020-09-18 2022-03-24
CA3201499A1 (en) 2020-11-13 2022-05-19 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
US12540141B2 (en) 2020-11-23 2026-02-03 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2022109360A1 (en) 2020-11-23 2022-05-27 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
US11352363B1 (en) 2020-11-23 2022-06-07 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11384090B2 (en) 2020-11-23 2022-07-12 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
EP4251645A1 (en) 2020-11-25 2023-10-04 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
EP4319876A1 (en) 2021-04-07 2024-02-14 Fujifilm Cellular Dynamics, Inc. Dopaminergic precursor cells and methods of use
US11319325B1 (en) 2021-05-11 2022-05-03 Enanta Pharmaceuticals, Inc. Macrocyclic spiropyrrolidine derived antiviral agents
WO2022251443A1 (en) 2021-05-26 2022-12-01 FUJIFILM Cellular Dynamics, Inc. Methods to prevent rapid silencing of genes in pluripotent stem cells
JP2024520423A (ja) 2021-05-28 2024-05-24 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 弱接着細胞を収容するための二次マトリックスを有する生分解性組織スキャフォールド
WO2022251499A1 (en) 2021-05-28 2022-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods to generate macular, central and peripheral retinal pigment epithelial cells
US11325916B1 (en) 2021-07-29 2022-05-10 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11339170B1 (en) 2021-07-23 2022-05-24 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
EP4402249A1 (en) 2021-09-13 2024-07-24 Fujifilm Cellular Dynamics, Inc. Methods for the production of committed cardiac progenitor cells
CN114107378A (zh) * 2021-09-13 2022-03-01 钦元再生医学(珠海)有限公司 一种通用型car-t细胞的制备方法
AU2022376962A1 (en) 2021-10-29 2024-04-18 FUJIFILM Cellular Dynamics, Inc. Dopaminergic neurons comprising mutations and methods of use thereof
WO2023172514A1 (en) 2022-03-07 2023-09-14 Catamaran Bio, Inc. Engineered immune cell therapeutics targeted to her2 and methods of use thereof
KR20250067762A (ko) * 2022-04-08 2025-05-15 뉴욕 스템 셀 파운데이션, 인코포레이티드 iPSC의 생산 방법
CN119630695A (zh) 2022-06-08 2025-03-14 世纪治疗股份有限公司 表达cd16变体和nkg2d的遗传工程化细胞及其用途
US20240003871A1 (en) 2022-06-29 2024-01-04 FUJIFILM Cellular Dynamics, Inc. Ipsc-derived astrocytes and methods of use thereof
WO2024050534A2 (en) * 2022-09-01 2024-03-07 Regents Of The University Of Minnesota In vitro generated hematopoietic stem progenitor cells and t cells and methods of making and using the same
WO2024073776A1 (en) 2022-09-30 2024-04-04 FUJIFILM Cellular Dynamics, Inc. Methods for the production of cardiac fibroblasts
WO2024102838A1 (en) 2022-11-09 2024-05-16 Century Therapeutics, Inc. Engineered interleukin-7 receptors and uses thereof
WO2024192329A1 (en) 2023-03-16 2024-09-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for producing stable human chondroctyes and their use for promoting cartillage growth and repair
CN118272437B (zh) * 2024-04-11 2024-12-17 广州瑞铂茵健康科技有限公司 一种诱导性多能干细胞及其制备方法和应用
WO2025245202A1 (en) 2024-05-21 2025-11-27 FUJIFILM Cellular Dynamics, Inc. Particle counting and biomass measurements of aggregated cell compositions
CN119280412B (zh) * 2024-09-24 2025-12-12 沈阳药科大学 触发细胞外囊泡级联渗透的工程化细胞膜囊泡及其构建方法和应用
US20260226420A1 (en) 2025-01-31 2026-08-06 FUJIFILM Holdings America Corporation Methods for the production of hepatic stellate cells from human pluripotent stem cells

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US172079A (en) 1876-01-11 Improvement in grinding-disks
US4002173A (en) 1974-07-23 1977-01-11 International Paper Company Diester crosslinked polyglucan hydrogels and reticulated sponges thereof
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
NL8200523A (nl) 1982-02-11 1983-09-01 Univ Leiden Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna.
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
US4952500A (en) 1988-02-01 1990-08-28 University Of Georgia Research Foundation, Inc. Cloning systems for Rhodococcus and related bacteria
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
DK0604662T3 (da) 1992-07-07 2008-10-20 Japan Tobacco Inc Fremgangsmåde til transformering af monocotyledon
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
AU670316B2 (en) 1992-07-27 1996-07-11 Pioneer Hi-Bred International, Inc. An improved method of (agrobacterium)-mediated transformation of cultured soybean cells
DE4228457A1 (de) 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
EP0711345A1 (en) 1993-07-26 1996-05-15 Dana Farber Cancer Institute B7-2: ctl a4/cd 28 counter receptor
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
GB9502022D0 (en) 1995-02-02 1995-03-22 Abuljadayel Ilham M S A method for preparing lymphohaematopoietic progenitor cells
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
DE19635568C1 (de) 1996-09-02 1998-03-26 Gsf Forschungszentrum Umwelt Vektorsysteme zur konditionalen Genexpression
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
WO1999020740A2 (en) 1997-10-23 1999-04-29 Geron Corporation Methods and materials for the growth of primate-derived primordial stem cells
US20030211603A1 (en) 2001-08-14 2003-11-13 Earp David J. Reprogramming cells for enhanced differentiation capacity using pluripotent stem cells
US7763466B2 (en) 2002-05-17 2010-07-27 Mount Sinai School Of Medicine Of New York University Mesoderm and definitive endoderm cell populations
JP2004194720A (ja) 2002-12-16 2004-07-15 Toray Ind Inc リガンド固定化カラム
US7790039B2 (en) 2003-11-24 2010-09-07 Northwest Biotherapeutics, Inc. Tangential flow filtration devices and methods for stem cell enrichment
US7347352B2 (en) 2003-11-26 2008-03-25 Kulicke And Soffa Industries, Inc. Low loop height ball bonding method and apparatus
US7452718B2 (en) 2004-03-26 2008-11-18 Geron Corporation Direct differentiation method for making cardiomyocytes from human embryonic stem cells
CA2565115A1 (en) 2004-05-03 2005-11-10 Peter Maccallum Cancer Institute Methods for stem cell expansion and differentiation
US7465580B2 (en) 2004-05-19 2008-12-16 Wisconsin Alumni Research Foundation Non-cytotoxic oriP replicon
US20080038820A1 (en) 2004-06-22 2008-02-14 Rudy-Reil Diane E Induction of pluripotent stem cells into mesodermal lineages
JP2006067858A (ja) 2004-08-31 2006-03-16 Dai Ichi Seiyaku Co Ltd 共培養による造血幹細胞の増幅方法
BRPI0514641A (pt) 2004-09-08 2008-06-17 Wisconsin Alumni Res Found cultivação das células tronco embriÈnica humana
EP1838844A4 (en) 2004-12-22 2008-11-26 Ip Organisers Pty Ltd DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS AND CARDIOMYOCYTES AND CARDIOMYOCYTIC DERIVATIVES DERIVED THEREFROM
US7606580B2 (en) 2005-05-11 2009-10-20 Aol Llc Personalized location information for mobile devices
JP4839021B2 (ja) 2005-06-10 2011-12-14 国立大学法人 岡山大学 白血球及び／又は造血幹・前駆細胞動員剤
US20090252711A1 (en) 2006-05-11 2009-10-08 Andrew Craig Boquest Stem Cells And Methods Of Making And Using Stem Cells
CN101460188B (zh) 2006-06-07 2013-09-04 国立大学法人德岛大学 使用促红细胞生成素的局部缺血疾病的治疗
SI2066351T1 (sl) 2006-10-02 2016-02-29 E.R. Squibb & Sons, L.L.C. Humana protitelesa, ki vežejo cxcr4 in njihova uporaba
US7777395B2 (en) * 2006-10-12 2010-08-17 Eastman Kodak Company Continuous drop emitter with reduced stimulation crosstalk
DK3399025T3 (da) 2007-03-23 2025-06-16 Wisconsin Alumni Res Found Omprogrammering af somatiske celler
JP2008237136A (ja) * 2007-03-28 2008-10-09 Foundation For Biomedical Research & Innovation ヒト造血細胞の培養方法
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
US20120282229A1 (en) 2007-08-01 2012-11-08 Christian Kannemeier Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state
WO2009032194A1 (en) 2007-08-31 2009-03-12 Whitehead Institute For Biomedical Research Wnt pathway stimulation in reprogramming somatic cells
EP2072618A1 (en) 2007-12-14 2009-06-24 Johannes Gutenberg-Universität Mainz Use of RNA for reprogramming somatic cells
WO2009091543A1 (en) 2008-01-14 2009-07-23 Lindner Scott E An efficient orip/ebna-1 plasmid vector
EP2268796A1 (en) 2008-03-17 2011-01-05 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Vectors and methods for generating vector-free induced pluripotent stem (ips) cells using site-specific recombination
EP2103685A1 (en) 2008-03-20 2009-09-23 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Vectors and methods for generating vector-free induced pluripotent stem (iPS) cells using site-specific recombination
CN101550406B (zh) 2008-04-03 2016-02-10 北京大学 制备多潜能干细胞的方法,试剂盒及用途
JP5346925B2 (ja) 2008-05-02 2013-11-20 国立大学法人京都大学 核初期化方法
ES2587395T3 (es) 2008-06-04 2016-10-24 Cellular Dynamics International, Inc. Procedimientos para la producción de células IPS usando un enfoque no vírico
CA2695590C (en) 2008-06-27 2018-01-09 Kyoto University Method of efficiently establishing induced pluripotent stem cells
EP3450545B1 (en) 2008-10-24 2023-08-23 Wisconsin Alumni Research Foundation Pluripotent stem cells obtained by non-viral reprogramming
WO2010131747A1 (ja) 2009-05-15 2010-11-18 国立大学法人 東京大学 ウイルス産生細胞
CN105925535A (zh) 2009-06-05 2016-09-07 细胞动力国际有限公司 重编程t细胞和造血细胞的方法
CA2766049A1 (en) 2009-06-19 2010-12-23 The Salk Institute For Biological Studies Generation of induced pluripotent stem cells from cord blood
WO2011032166A2 (en) 2009-09-14 2011-03-17 The Johns Hopkins University Reprogramming blood cells to pluripotent and multipotent stem cells
CA2802249A1 (en) 2010-06-15 2011-12-22 Cellular Dynamics International, Inc. Generation of induced pluripotent stem cells from small volumes of peripheral blood
EP2601289B1 (en) 2010-08-04 2017-07-12 Cellular Dynamics International, Inc. Reprogramming immortalized b cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6014021670; Ｙｕｉｎ-Ｈａｎ　Ｌｏｈ　ｅｔ　ａｌ．: 'Ｇｅｎｅｒａｔｉｏｎ　ｏｆ　ｉｎｄｕｃｅｄ　ｐｌｕｒｉｐｏｔｅｎｔ　ｓｔｅｍ　ｃｅｌｌｓ　ｆｒｏｍ　ｈｕｍａｎ　ｂｌｏｏｄ' Ｂｌｏｏｄ Ｖｏｌ．１１３，　Ｎｏ．２２, 20090528, Ｐａｇｅｓ　５４７６-５４７９ *
JPN6014021671; Ｚｈｏｕ　Ｈ　ｅｔ　ａｌ．: 'Ｇｅｎｅｒａｔｉｏｎ　ｏｆ　ｉｎｄｕｃｅｄ　ｐｌｕｒｉｐｏｔｅｎｔ　ｓｔｅｍ　ｃｅｌｌｓ　ｕｓｉｎｇ　ｒｅｃｏｍｂｉｎａｎｔ　ｐｒｏｔｅｉｎｓ' Ｃｅｌｌ　Ｓｔｅｍ　Ｃｅｌｌ Ｖｏｌ．　４，　Ｎｏ．５, 20090508, Ｐａｇｅｓ　３８１-３８４ *
JPN6014021672; Ｎｉｍｅｔ　Ｍａｈｅｒａｌｉ　ｅｔ　ａｌ．: 'Ｇｕｉｄｅｌｉｎｅｓ　ａｎｄ　Ｔｅｃｈｎｉｑｕｅｓ　ｆｏｒ　ｔｈｅ　Ｇｅｎｅｒａｔｉｏｎ　ｏｆ　Ｉｎｄｕｃｅｄ　Ｐｌｕｒｉｐｏｔｅｎｔ　Ｓｔｅｍ　Ｃｅｌｌｓ' Ｃｅｌｌ　Ｓｔｅｍ　Ｃｅｌｌ Ｖｏｌｕｍｅ　３，　Ｉｓｓｕｅ　６, 20081204, Ｐａｇｅｓ　５９５-６０５ *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10787642B2 (en) 2010-02-03 2020-09-29 The University Of Tokyo Method for reconstructing immune function using pluripotent stem cells
US9206394B2 (en) 2010-02-03 2015-12-08 The University Of Tokyo Method for reconstructing immune function using pluripotent stem cells
US12024717B2 (en) 2010-02-03 2024-07-02 The University Of Tokyo Method for reconstructing immune function using pluripotent stem cells
JP2013528397A (ja) * 2010-06-15 2013-07-11 セルラー ダイナミクス インターナショナル， インコーポレイテッド 少量の末梢血からの人工多能性幹細胞の作製
US10260048B2 (en) 2010-06-15 2019-04-16 FUJIFILM Cellular Dynamics, Inc. Generation of induced pluripotent stem cells from small volumes of peripheral blood
JP2015146803A (ja) * 2014-01-10 2015-08-20 学校法人 聖マリアンナ医科大学 メラノサイトの分化誘導方法
JP7370529B2 (ja) 2015-08-31 2023-10-30 剛士 田邊 多能性幹細胞製造システム、幹細胞の誘導方法、幹細胞の浮遊培養方法、幹細胞の浮遊培養器、人工多能性幹細胞の作製方法、及び動物細胞から特定の体細胞を作製する方法
US11286454B2 (en) 2015-08-31 2022-03-29 I Peace, Inc. Pluripotent stem cell manufacturing system and method for producing induced pluripotent stem cells
JP2018526992A (ja) * 2015-08-31 2018-09-20 アイ ピース，インコーポレイテッド 多能性幹細胞製造システム、幹細胞の誘導方法、幹細胞の浮遊培養方法、幹細胞の浮遊培養器、人工多能性幹細胞の作製方法、及び動物細胞から特定の体細胞を作製する方法
JPWO2018143243A1 (ja) * 2017-02-03 2019-11-21 国立大学法人神戸大学 人工多能性幹細胞の作製方法
JP7224021B2 (ja) 2017-02-03 2023-02-17 国立大学法人神戸大学 人工多能性幹細胞の作製方法
WO2018143243A1 (ja) * 2017-02-03 2018-08-09 国立大学法人神戸大学 人工多能性幹細胞の作製方法
JPWO2020013315A1 (ja) * 2018-07-13 2021-08-02 国立大学法人京都大学 γδＴ細胞の製造方法
JP7479635B2 (ja) 2018-07-13 2024-05-09 国立大学法人京都大学 γδＴ細胞の製造方法
JP2024096899A (ja) * 2018-07-13 2024-07-17 国立大学法人京都大学 γδＴ細胞の製造方法
JP7817708B2 (ja) 2018-07-13 2026-02-19 国立大学法人京都大学 γδＴ細胞の製造方法
JP2022513045A (ja) * 2018-11-16 2022-02-07 セルジーン コーポレイション 改善されたｔ細胞製造プロセス
JP2025020128A (ja) * 2018-11-16 2025-02-12 セルジーン コーポレイション 改善されたｔ細胞製造プロセス

Also Published As

Publication number Publication date
CN103087991A (zh) 2013-05-08
CN103087991B (zh) 2018-06-12
US8741648B2 (en) 2014-06-03
JP2018029622A (ja) 2018-03-01
IL261851A (en) 2018-10-31
IL261851B (en) 2020-06-30
DK2548950T3 (en) 2017-12-11
AU2010254811B2 (en) 2015-02-19
WO2010141801A2 (en) 2010-12-09
US10221396B2 (en) 2019-03-05
KR101813464B1 (ko) 2018-01-30
EP2548950A3 (en) 2013-02-20
JP2018183169A (ja) 2018-11-22
EP2548950A2 (en) 2013-01-23
EP2548950B1 (en) 2017-10-25
JP2020124197A (ja) 2020-08-20
JP2017104140A (ja) 2017-06-15
DK2438160T3 (en) 2016-01-11
CA2764373A1 (en) 2010-12-09
IL216707A0 (en) 2012-02-29
US20120135525A1 (en) 2012-05-31
US20140315304A1 (en) 2014-10-23
WO2010141801A3 (en) 2011-03-31
EP2438160A2 (en) 2012-04-11
DK3150701T3 (en) 2019-01-14
US20170226484A1 (en) 2017-08-10
KR20160113327A (ko) 2016-09-28
JP2018198604A (ja) 2018-12-20
IL216707B (en) 2019-03-31
KR101811235B1 (ko) 2017-12-21
JP2014217393A (ja) 2014-11-20
US9347044B2 (en) 2016-05-24
EP2438160B1 (en) 2015-12-23
EP3150701A1 (en) 2017-04-05
KR101772860B1 (ko) 2017-08-30
KR20170055562A (ko) 2017-05-19
KR20120026125A (ko) 2012-03-16
CN102459575A (zh) 2012-05-16
JP2021000131A (ja) 2021-01-07
US20160257939A1 (en) 2016-09-08
EP3150701B1 (en) 2018-10-03
CA2952805C (en) 2021-06-01
AU2010254811A1 (en) 2011-12-01
CA2764373C (en) 2019-11-19
CN105925535A (zh) 2016-09-07
CA2952805A1 (en) 2010-12-09
JP2020022462A (ja) 2020-02-13
JP6865199B2 (ja) 2021-04-28

Similar Documents

Publication Publication Date Title
JP6865199B2 (ja) リプログラミングｔ細胞および造血細胞
KR102857712B1 (ko) 면역 세포로의 만능 줄기 세포의 지정된 분화 방법
CN110023491B (zh) 多能干细胞定向分化为hla纯合免疫细胞的方法
KR101861168B1 (ko) 작은 부피의 말초 혈액으로부터의 유도된 만능 줄기 세포의 생성
JP2020010704A (ja) 多能性幹細胞を用いた免疫機能再建法
AU2015200413B2 (en) Reprogramming t cells and hematopoietic cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140826

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150805

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150827

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20151016

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170317

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20180124

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20180215